Gene · 92521
Papers3,158
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,821 to 1,840 of 3,158
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Characterization of Hepatitis B Virus Integrations Identified in Hepatocellular Carcinoma Genomes. | Viruses | 2021 | 33557409 | PubTator, text mining | PubMed |
| SARS-CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges. | Infect Dis Rep | 2021 | 33557330 | PubTator, text mining | PubMed |
| COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics-a review. | Arch Microbiol | 2021 | 33555378 | PubTator, text mining | PubMed |
| Structural insights into SARS-CoV-2 infection and therapeutics development. | Stem Cell Res | 2021 | 33550140 | PubTator, text mining | PubMed |
| Mutational analysis and assessment of its impact on proteins of SARS-CoV-2 genomes from India. | Gene | 2021 | 33549714 | PubTator, text mining | PubMed |
| Detecting SARS-CoV-2 3CLpro expression and activity using a polyclonal antiserum and a luciferase-based biosensor. | Virology | 2021 | 33548599 | PubTator, text mining | PubMed |
| Probing SARS-CoV-2 sequence diversity of Pakistani isolates. | Infect Genet Evol | 2021 | 33545393 | PubTator, text mining | PubMed |
| Systematically defining selective autophagy receptor-specific cargo using autophagosome content profiling. | Mol Cell | 2021 | 33545068 | PubTator, text mining | PubMed |
| Uncovering potential host proteins and pathways that may interact with eukaryotic short linear motifs in viral proteins of MERS, SARS and SARS2 coronaviruses that infect humans. | PLoS One | 2021 | 33534852 | PubTator, text mining | PubMed |
| Genomic variations in patients with myelodysplastic syndrome and karyotypes without numerical or structural changes. | Sci Rep | 2021 | 33531543 | PubTator, text mining | PubMed |
| Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. | Nat Commun | 2021 | 33531496 | PubTator, text mining | PubMed |
| De novo design and bioactivity prediction of SARS-CoV-2 main protease inhibitors using recurrent neural network-based transfer learning. | BMC Chem | 2021 | 33531083 | PubTator, text mining | PubMed |
| One Year of SARS-CoV-2: How Much Has the Virus Changed? | Biology (Basel) | 2021 | 33530355 | PubTator, text mining | PubMed |
| Identification of natural compounds as potent inhibitors of SARS-CoV-2 main protease using combined docking and molecular dynamics simulations. | Saudi J Biol Sci | 2021 | 33526965 | PubTator, text mining | PubMed |
| Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP. | Proc Natl Acad Sci U S A | 2021 | 33526596 | PubTator, text mining | PubMed |
| Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2. | Antimicrob Agents Chemother | 2021 | 33526482 | PubTator, text mining | PubMed |
| Insights of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) pandemic: a current review. | Biol Proced Online | 2021 | 33526007 | PubTator, text mining | PubMed |
| The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis. | Int J Mol Sci | 2021 | 33525632 | PubTator, text mining | PubMed |
| Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus. | Results Chem | 2021 | 33520632 | PubTator, text mining | PubMed |
| Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach. | 3 Biotech | 2021 | 33520579 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/92521/papers?page=92